TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22584544

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl wafer (100 μg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: IV fentanyl (100 μg)
Number of subjects: 24
Study: 20425759

Group type: EXPERIMENTAL
Intervention: FV capsules
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: FVB capsules
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 17672262

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide liner (Hydro C)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Gutta-percha sheet
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 39
Study: 15689195

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (10 mg)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (2 g)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 113
Study: 11981123

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 365) informed of test results and invited for further assessment by a senior physician.
Number of subjects: 978

Group type: COMPARATOR
Intervention: Control group (n = 302) left with information of high GT value and followed up with laboratory checkups every 2nd year.
Number of subjects: 978
Study: 9730078

Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 336
Study: 7614898

Group type: EXPERIMENTAL
Intervention: Zidovudine (100 mg five times daily until onset of labour, followed by intravenous zidovudine 2 mg/kg over 1 hour then 1 mg/kg.h until delivery)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Zidovudine syrup (2 mg/kg administered 6-hourly for 6 weeks)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 400
Study: 1975321

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK, 1.5 MU infused intravenously over 30‐60 min)
Number of subjects: 12490

Group type: EXPERIMENTAL
Intervention: Alteplase (tPA, 100 mg infused intravenously over 3 h)
Number of subjects: 12490

Group type: EXPERIMENTAL
Intervention: Heparin (12,500 U subcutaneously twice daily until discharge, starting 12 h after beginning the tPA or SK infusion)
Number of subjects: 12490

Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 12490

Group type: EXPERIMENTAL
Intervention: SK and heparin
Number of subjects: 12490

Group type: EXPERIMENTAL
Intervention: tPA and heparin
Number of subjects: 12490

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 12490

Group type: EXPERIMENTAL
Intervention: SK and tPA
Number of subjects: 12490
Study: 4913961

Group type: EXPERIMENTAL
Intervention: Oral ergotamine tartrate (2 or 3 mg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Oral ergotamine tartrate
Number of subjects: 79
Study: 30997721

Group type: EXPERIMENTAL
Intervention: Integrated prevention program
Number of subjects: 388

Group type: COMPARATOR
Intervention: Study skills control
Number of subjects: 388

Group type: COMPARATOR
Intervention: Nonintervention control
Number of subjects: 388
Study: 28668386

Group type: EXPERIMENTAL
Intervention: Transplantation group (R-CHOP-14 followed by R-MAD plus BEAM and autologous stem-cell transplantation)
Number of subjects: 399

Group type: COMPARATOR
Intervention: No transplantation group (full course of rituximab-dose-dense chemotherapy)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Transplantation group
Number of subjects: 399

Group type: COMPARATOR
Intervention: No transplantation group
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 399
Study: 26036621

Group type: EXPERIMENTAL
Intervention: Caregiving stress and life stress
Number of subjects: 300
Study: 24007322

Group type: EXPERIMENTAL
Intervention: 63 Gy in 20 fractions (4 fractions/week) (Arm 2)
Number of subjects: 124

Group type: COMPARATOR
Intervention: 76 Gy in 38 fractions (5 fractions/week) (Arm 1)
Number of subjects: 124
Study: 21719078

Group type: EXPERIMENTAL
Intervention: Anti-IL-13 (6 mg/kg intravenously)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nasal corticosteroid (fluticasone)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19327467

Group type: EXPERIMENTAL
Intervention: Nafamostat mesylate (20 mg) with 5% dextrose solution
Number of subjects: 704

Group type: COMPARATOR
Intervention: Control (without nafamostat mesylate)
Number of subjects: 704
Study: 16352815

Group type: EXPERIMENTAL
Intervention: Deferiprone (92 mg/kg/d)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Deferoxamine (43 mg/kg for 5.7 d/wk)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 61
Study: 15285851

Group type: EXPERIMENTAL
Intervention: lansoprazole (30 mg per day for 4 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: rabeprazole (10 mg per day for 4 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: control (without lansoprazole or rabeprazole)
Number of subjects: 19
Study: 10708167

Group type: EXPERIMENTAL
Intervention: Acute hypercapnia (Paco2 from 40+/‐3 to 52+/‐3 torr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acute hypocapnia (Paco2 from 41+/‐3 to 34+/‐3 torr)
Number of subjects: 10
Study: 9094882

Group type: EXPERIMENTAL
Intervention: Tube feeding
Number of subjects: 17

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 17
Study: 8195854

Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 50

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 50
Study: 3721943

Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) 1g, 2g, 3g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lorazepam 3 mg
Number of subjects: 10
Study: 31630052

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30242986

Group type: EXPERIMENTAL
Intervention: Multi-therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Mono-therapy
Number of subjects: 240
Study: 26781004

Group type: EXPERIMENTAL
Intervention: DRV/r
Number of subjects: 75

Group type: COMPARATOR
Intervention: LPV/r
Number of subjects: 75
Study: 23244034

Group type: EXPERIMENTAL
Intervention: Positive affect intervention
Number of subjects: 5

Group type: COMPARATOR
Intervention: Greedy divisions of money or labor
Number of subjects: 5

Group type: COMPARATOR
Intervention: Equal divisions of money or labor
Number of subjects: 5

Group type: COMPARATOR
Intervention: Generous divisions of money or labor
Number of subjects: 5
Study: 23262045

Group type: EXPERIMENTAL
Intervention: Prograf
Number of subjects: 82

Group type: COMPARATOR
Intervention: Advagraf
Number of subjects: 82
Study: 20605872

Group type: EXPERIMENTAL
Intervention: Higher protein omnivorous diet (30% energy from protein with 40% from lean pork)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Normal protein vegetarian diet (18% energy from protein via lacto-ovo vegetarian sources)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nonmeat protein sources (16% energy from protein)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Chicken (26% energy from protein)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Beef (26% energy from protein)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 82
Study: 18398024

Group type: EXPERIMENTAL
Intervention: Having health insurance coverage
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Having health insurance coverage (men)
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Having health insurance coverage (women)
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Having health insurance coverage (adjusted for age and income, men)
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Having health insurance coverage (adjusted for age and income, women)
Number of subjects: 2887
Study: 15812731

Group type: EXPERIMENTAL
Intervention: Internet/video-delivered intervention (8 sessions)
Number of subjects: 104
Study: 11919104

Group type: EXPERIMENTAL
Intervention: Nebulised levo-adrenaline (3 mg in 3 ml)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.9% saline placebo
Number of subjects: 38
Study: 10394803

Group type: EXPERIMENTAL
Intervention: Mild controlled hypothermia (Core temperature = 33‐35 degrees C)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 5
Study: 7595101

Group type: EXPERIMENTAL
Intervention: Sitostanol ester margarine (3 g/day)
Number of subjects: 15
Study: 1850942

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 8

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 8
Study: 7053889

Group type: EXPERIMENTAL
Intervention: RAO projection
Number of subjects: 32

Group type: COMPARATOR
Intervention: LAO projection
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bolus FWHM
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sequential studies
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Wall motion assessment
Number of subjects: 32
Study: 30516029

Group type: EXPERIMENTAL
Intervention: 15-gene immune-related risk signature
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: High-immune risk patients
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Gene set enrichment analysis (GSEA) results
Number of subjects: 285
Study: 28225739

Group type: EXPERIMENTAL
Intervention: Damage Control Laparotomy (DCL)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Definitive Surgical Management
Number of subjects: 329
Study: 25517348

Group type: EXPERIMENTAL
Intervention: Intraarterial treatment plus usual care
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 500
Study: 23975185

Group type: EXPERIMENTAL
Intervention: Balance training three times a week for 6 weeks during pulmonary rehabilitation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group received only the 6-week pulmonary rehabilitation program
Number of subjects: 39
Study: 22108352

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) correction
Number of subjects: 114

Group type: COMPARATOR
Intervention: Contact lens correction
Number of subjects: 114
Study: 19740082

Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 60
Study: 17006667

Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 30
Study: 15567189

Group type: EXPERIMENTAL
Intervention: Mirtazapine treatment for 8 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 25
Study: 11395198

Group type: EXPERIMENTAL
Intervention: Osmolality of 300, 600, 850, and 1100 mOsm during intramuscular injection of 0.5 ml vaccine suspensions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 20
Study: 9121645

Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of meglumine ioglycate, 300 mg/ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 ml/kg of meglumine ioglycate, 300 mg/ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.25 ml/kg of meglumine ioglycate, 300 mg/ml
Number of subjects: 60
Study: 8398292

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) - 9 instillations
Number of subjects: 437

Group type: COMPARATOR
Intervention: BCG-Tice - 6 weekly instillations
Number of subjects: 437

Group type: COMPARATOR
Intervention: BCG-RIVM - 6 weekly instillations
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: All treatments (MMC, BCG-Tice, BCG-RIVM)
Number of subjects: 437
Study: 3297218

Group type: EXPERIMENTAL
Intervention: Low dose prednisone (0.5 mg/kg body weight)
Number of subjects: 143

Group type: COMPARATOR
Intervention: High dose prednisone (2.0 mg/kg body weight)
Number of subjects: 143
Study: 31327047

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet plus Bacillus coagulans supplementation (109 B. coagulans spores and 400 mg inulin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low FODMAP diet alone (placebo with 500 mg rice starch)
Number of subjects: 50
Study: 29404948

Group type: EXPERIMENTAL
Intervention: Mastery learning course with visual and dermoscopic assessment, diagnosis and management, and deliberate practice with feedback.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Mastery learning course
Number of subjects: 89
Study: 25257848

Group type: EXPERIMENTAL
Intervention: Hypoxic exercise (FIO2 = 0·12‐0·13)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normoxic exercise (FIO2 = 0·21)
Number of subjects: 7
Study: 24920046

Group type: EXPERIMENTAL
Intervention: Home Based Telemedicine
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 168
Study: 22843218

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection (painful)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isotonic saline injection (control)
Number of subjects: 15
Study: 20716636

Group type: EXPERIMENTAL
Intervention: Sad mood individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Happy mood individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive mood individuals
Number of subjects: 0
Study: 18561925

Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol sedation (NAPS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam and meperidine (M/M)
Number of subjects: 80
Study: 16105183

Group type: EXPERIMENTAL
Intervention: Glycine (multiple intravenous doses)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 12544402

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV)
Number of subjects: 37868

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 37868
Study: 11018577

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8843257

Group type: EXPERIMENTAL
Intervention: HA membrane
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (no HA membrane)
Number of subjects: 183
Study: 1353134

Group type: EXPERIMENTAL
Intervention: ST waveform analysis plus CTG
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Conventional cardiotocography (CTG)
Number of subjects: 1200
Study: 6504708

Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomer combinations (10 mg (−) enantiomer + 40, 90, and 140 mg (+) enantiomer)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomer combinations
Number of subjects: 10
Study: 31892686

Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PRF + Collaplug
Number of subjects: 54

Group type: COMPARATOR
Intervention: No preservation
Number of subjects: 54
Study: 29511971

Group type: EXPERIMENTAL
Intervention: Continuous non-invasive blood pressure monitoring (CS group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent BP cuff measurement (Control group)
Number of subjects: 40
Study: 27270228

Group type: EXPERIMENTAL
Intervention: Tm1Tm2 (two different mediators)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tm1Tm1 (one mediator)
Number of subjects: 0
Study: 25018804

Group type: EXPERIMENTAL
Intervention: Oral steroids
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous and oral steroids
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous steroids
Number of subjects: 150
Study: 22331983

Group type: EXPERIMENTAL
Intervention: B vitamins (5-methyltetrahydrofolate 0.56 mg, vitamin B6 3 mg, vitamin B12 0.02 mg)
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids (eicosapentaenoic and docosahexaenoic acid 600 mg)
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: B vitamins and ω-3 fatty acids
Number of subjects: 2501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2501
Study: 20642481

Group type: EXPERIMENTAL
Intervention: Double kissing (DK) crush
Number of subjects: 51

Group type: COMPARATOR
Intervention: Provisional 1-stent
Number of subjects: 51
Study: 17998836

Group type: EXPERIMENTAL
Intervention: Group-based education programme for patients with mild GORD
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Group-based education programme for patients with mild GORD (specifically for those with primary school education)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (no education programme)
Number of subjects: 211
Study: 15726309

Group type: EXPERIMENTAL
Intervention: Marker clip placement at biopsy site
Number of subjects: 79
Study: 12213517

Group type: EXPERIMENTAL
Intervention: D-amphetamine (AMPH; 15 mg oral)
Number of subjects: 20
Study: 9708229

Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasound
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Amplitude ultrasound angiography
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Real time grey scale imaging
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasound after embolotherapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Spectral wave analysis
Number of subjects: 6
Study: 7745465

Group type: EXPERIMENTAL
Intervention: Heparin (continuous intravenous infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of anticoagulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoidance of aspirin and NSAIDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfusions to maintain platelet count above 50,000
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolytics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vena caval filters and thrombectomy
Number of subjects: 0
Study: 2809170

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain detergent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 0
Study: 31307527

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (a combination of aerobic and resistance training with progressive intensity and volume, three times per week during ACT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard BC care (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 90
Study: 28647169

Group type: EXPERIMENTAL
Intervention: Same-day preschool vaccinations (number of injections between ages four and six years)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Upper quartile of needle fear (VAS≥83)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Parent vaccine anxiety (VAS>50)
Number of subjects: 120
Study: 25405571

Group type: EXPERIMENTAL
Intervention: Low-dose estradiol (E2) 0.5 mg/day
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg/day
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 23644225

Group type: EXPERIMENTAL
Intervention: Surgical treatment with UPPP
Number of subjects: 65

Group type: COMPARATOR
Intervention: Expectancy (control group)
Number of subjects: 65
Study: 22013952

Group type: EXPERIMENTAL
Intervention: 200 ml of 20% albumin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200 ml of 4% gelatin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 10
Study: 18818699

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34)
Number of subjects: 69

Group type: COMPARATOR
Intervention: CHOP (n=30)
Number of subjects: 69
Study: 16698659

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 15228864

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 0.75 ml/kg along with 0.1% midazolam 50mg/kg (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.25% bupivacaine 0.75 ml/kg (group A)
Number of subjects: 60
Study: 11953729

Group type: EXPERIMENTAL
Intervention: Indwelling catheter injections
Number of subjects: 41

Group type: COMPARATOR
Intervention: Insulin pens with standard needles (Control)
Number of subjects: 41
Study: 9832299

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times a day for 4 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg once a day for 4 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7867751

Group type: EXPERIMENTAL
Intervention: Operant conditioning training for biceps brachii SSRs over 24 sessions in 8 weeks.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no training) during the same period.
Number of subjects: 17
Study: 2553425

Group type: EXPERIMENTAL
Intervention: HPTH 1-38 (35 micrograms)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: HPTH 1-38 (17.5 micrograms)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: HPTH 1-38 (8.75 micrograms)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: HPTH 1-38 (all doses)
Number of subjects: 7
Study: 1026548

Group type: EXPERIMENTAL
Intervention: Forewarned about side-effects (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not forewarned about side-effects (Group B)
Number of subjects: 100
Study: 28859083

Group type: EXPERIMENTAL
Intervention: Community health worker intervention (CHW integration with PMTCT services)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Standard of care (comparison group)
Number of subjects: 1
Study: 25504995

Group type: EXPERIMENTAL
Intervention: AICS-Bud 1 mg
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: AICS-Bud 0.5 mg
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: COMPARATOR
Intervention: CN-Bud
Number of subjects: 199
Study: 23131756

Group type: EXPERIMENTAL
Intervention: 400 μg/kg ivermectin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 6
Study: 21067837

Group type: EXPERIMENTAL
Intervention: Continuation of glimepiride
Number of subjects: 25

Group type: COMPARATOR
Intervention: Discontinuation of glimepiride
Number of subjects: 25
Study: 19580019

Group type: EXPERIMENTAL
Intervention: Bupivacaine scalp infiltration
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 36